Clinical Trial: Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention o

Brief Summary: This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Detailed Summary:
Sponsor: GlaxoSmithKline

Current Primary Outcome: Rates of vomiting and retching [ Time Frame: after surgery ]

Original Primary Outcome: Rates of vomiting and retching after surgery.

Current Secondary Outcome: Rates of nausea. Blood test results. [ Time Frame: after surgery ]

Original Secondary Outcome: Rates of nausea after surgery. Blood test results.

Information By: GlaxoSmithKline

Dates:
Date Received: May 12, 2006
Date Started: March 2006
Date Completion:
Last Updated: October 24, 2016
Last Verified: October 2016